A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants - Trial NCT06315335
Access comprehensive clinical trial information for NCT06315335 through Pure Global AI's free database. This Phase 1 trial is sponsored by UCB Biopharma SRL and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
UCB Biopharma SRL
UCB Pharma
Timeline & Enrollment
Phase 1
Jul 01, 2024
Jul 29, 2025
Primary Outcome
Occurrence of TEAEs,Occurrence of treatment-emergent SAEs
Summary
The purpose of the study is investigate the safety, tolerability and pharmacokinetic of
 UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy
 Caucasian and Japanese participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06315335
Non-Device Trial

